Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Population of Relapse or Refractory Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FORTE)

NCT03873857 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03873857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03873857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Population of Relapse or Refractory Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FORTE)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
February 25, 2019
Completion date
September 12, 2022
Enrollment
71 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, chronic lymphocytic leukemia (cll)